PITTSBURGH--(BUSINESS WIRE)--Complexa, Inc., an inflammatory and metabolic disease-focused biopharmaceutical company announced today that it has initiated the first human clinical trial of lead product candidate CXA-10. The initial target indication is for the treatment of acute kidney injury related to the administration of contrast imaging agents in high-risk patients. This Phase I trial is designed to assess CXA-10’s safety and pharmacokinetics. Through the use of various biomarkers, the study will also demonstrate CXA-10’s mechanism of action and document target organ engagement that will further illuminate its regulation of critical inflammatory pathways.
Help employers find you! Check out all the jobs and post your resume.
